Juvmo Kit
NDC Package 0074-6090-40

11-digit billing NDC: 00074609040
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Juvmo (tavapadon) kits is jUVMO is indicated for the treatment of Parkinson’s disease (PD) in adults. This formulation utilizes a kit delivery system. Marketed by Abbvie Inc., this product is identified by NDC 0074-6090 and is authorized under FDA application NDA220415.

Identification & Billing

NDC Package Code
0074-6090-40
Package Description
1 KIT in 1 CARTON * 36 TABLET in 1 BLISTER PACK * 64 TABLET in 1 BLISTER PACK
Product Code
0074-6090
11-Digit Billing Format
00074609040

Clinical Specifications

Proprietary Name
Juvmo
Non-Proprietary Name
Tavapadon
Dosage Form
Kit - A packaged collection of related material.
Usage Information
JUVMO is indicated for the treatment of Parkinson’s disease (PD) in adults.

Regulatory & Marketing

Labeler Name
Abbvie Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA220415
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
09-25-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0074-6090-40 identifies a specific commercial package of 1 kit in 1 carton * 36 tablet in 1 blister pack * 64 tablet in 1 blister pack of Juvmo, a human prescription drug labeled by Abbvie Inc.. This kit is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Abbvie Inc. on September 25, 2026. The current certification is valid through December 31, 2027.

How is this Abbvie Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00074609040. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0074-6090-40
11-Digit CMS (5-4-2)
00074-6090-40

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.